Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Cetuximab (Erbitux) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-Line Chemotherapy.

Trial Profile

Phase II Study of Cetuximab (Erbitux) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-Line Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms EFFI; STAGE
  • Most Recent Events

    • 25 Dec 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top